Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older fragile patients with metastatic renal cell carcinoma: The SOGUG-CABOMAYOR study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Climent MA
  • Sanchez-Escribano R
  • Heras L
  • Basterretxea L
  • Guzmán JCV
  • Torregrosa D
  • Nuñez NF
  • Zambrana F
  • Llabres-Valenti E

Abstract

INTRODUCTION: The efficacy and tolerability of anticancer drugs may be affected by several factors that change with age. No specific trials of cabozantinib have been conducted in older patients with metastatic renal cell carcinoma (mRCC). The CABOMAYOR study was aimed at evaluating the efficacy in terms of objective response rate in previously untreated fragile older patients with mRCC. MATERIALS AND METHODS: An exploratory, phase 2, single-arm study was conducted in patients who were = 70 years with a risk of frailty or who were > 75 years regardless of frailty, had a diagnosis of mRCC with measurable disease, had an ECOG-PS of 0-2, and had not received previous treatment for mRCC. Cabozantinib was orally administered once daily at a dose of 40 mg for 28-day cycles, which could be increased to 60 mg to prevent suboptimal exposure. The primary endpoint was the objective response rate (ORR). Other outcomes included progression-free survival, overall survival and adverse events. RESULTS: Thirty-eight patients were screened, and 24 patients were included in the study. Patients had a median age of 78 years (interquartile range [IQR] 75-81), and 12 (50%) had a Geriatric-8 score equal to or less than 14 points (i.e., risk of frailty). The median duration of follow-up was 27.0 (16.6-47.1) months. There were no confirmed complete responses, and seven patients achieved a confirmed partial response, thus leading to an ORR of 29.2% (95% confidence interval [CI]: 11.0-47.4%). The median progression-free survival and overall survival were 2.8 (95% CI: 2.0-3.6) months and 33.7 (95% CI: 20.5-46.8) months, respectively. Fourteen (58.3%) patients required dose reductions, and 17 patients (70.8%) required dose interruptions, mostly due to nonhematologic toxicity. Most of the adverse events were grade 1-2 events. There were three grade 5 adverse events, none of which were considered treatment-related: these events included physical health deterioration, cerebral hemorrhage, or COVID-19-related pneumonia. Serious adverse events occurred in 11 (45.8%) patients, three of which were considered treatment-related. DISCUSSION: Our results suggest that cabozantinib is effective as an initial monotherapy for older patients with mRCC with a toxicity profile consistent with that reported in younger adults.

Copyright © 2025. Published by Elsevier Ltd.

Datos de la publicación

ISSN/ISSNe:
1879-4068, 1879-4076

Journal of Geriatric Oncology  ELSEVIER

Tipo:
Article
Páginas:
102340-102340
PubMed:
40834740
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,364 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Cabozantinib; Metastatic; Older adults; Renal cell carcinoma; Tyrosine kinase inhibitor

Cita

Compartir